Clinical Trial Update: Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating humoral and cell-mediated immunity and safety of MF59C.1-adjuvanted subunit influenza vaccine versus conventional subunit influe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Influenza Due to Influenza Virus

Drugs mentioned

• MF59C.1-adjuvanted subunit influenza vaccine
• conventional subunit influenza vaccine

Snippet

Sponsor: Novartis Vaccines | Conditions: Seasonal Influenza, Influenza | Phase 2 | Status: COMPLETED | Results posted: 2021-04-19